BioInnovation

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Vaxess Technologies is a biotechnology company focused on silk biomaterial platforms for vaccine and therapeutic delivery. It develops the MIMIX microneedle patch for transdermal, sustained-release delivery of vaccines and therapies, designed to improve stability and ease of use, including formulations that do not require cold chain storage. The MATRIX formulation and drying platform supports thermostable vaccine, therapeutic, and diagnostic products. The company aims to enable long-term immune responses and easier distribution, including in low-resource settings. Its technology supports oncology and infectious disease applications, including therapies that promote durable anti-tumor immunity and improved treatment outcomes. Founded in 2011 and based in Boston, the company positions its platforms to enable stable, targeted delivery and potentially reduce treatment burden for patients.

Cereius, Inc. is a pre-clinical stage biotechnology company based in Durham, North Carolina, focused on developing innovative small-molecule therapies for brain metastasis, particularly in patients with HER2-positive breast cancer. Incorporated in 2017, the company specializes in novel radiolabeling chemistries that enhance the uptake and retention of radionuclides in targeted tumors while reducing the absorption in healthy tissues. This approach significantly improves both the therapeutic index and the diagnostic contrast of targeting agents, enabling medical practitioners to more effectively treat solid tumor brain metastasis and potentially improve patient survival rates.

PanTher Therapeutics is a biotechnology company developing cancer drug-delivery technologies. Its core platform enables therapeutics to be delivered directly to the tumor site, reducing systemic toxicity and allowing higher drug concentrations at the target while enabling sustained treatment. This approach aims to improve therapeutic efficacy and outcomes for hard-to-treat cancers by maximizing drug exposure at the tumor while limiting exposure to healthy tissue. Headquartered in Cambridge, Massachusetts, PanTher Therapeutics is advancing investigational candidates, including a lead program in pancreatic cancer, to broaden the potential of precision delivery in oncology.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Avexegen Therapeutics Inc. is a development stage biotechnology company based in San Diego, California, founded in 2014. The company specializes in creating innovative therapies aimed at healing damaged and inflamed gut tissue in patients suffering from gastrointestinal disorders, particularly Crohn's disease and ulcerative colitis. Additionally, Avexegen focuses on addressing needs in premature infants with necrotizing enterocolitis. By employing a novel approach to treatment, Avexegen aims to improve the long-term health outcomes of patients with these serious conditions.

Sentien Biotechnologies, Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapies aimed at restoring immune system balance and improving treatment options for patients with systemic inflammatory diseases. The company specializes in proprietary cell compositions and Good Manufacturing Practice (GMP) manufacturing methods that enhance the efficacy of cell therapy. Its flagship product, SBI-101, utilizes an extracorporeal device to immobilize Mesenchymal Stromal Cells (MSCs), facilitating sustained and controlled delivery of their therapeutic properties, which include anti-inflammatory and regenerative effects. Additionally, the company offers the Sentinel device, designed to treat patients during dialysis by supplementing their blood with MSC-derived secretions that address immune dysfunction and promote tissue repair. Founded in 2008, Sentien Biotechnologies is headquartered in Medford, Massachusetts.

Vaxess Technologies is a biotechnology company focused on silk biomaterial platforms for vaccine and therapeutic delivery. It develops the MIMIX microneedle patch for transdermal, sustained-release delivery of vaccines and therapies, designed to improve stability and ease of use, including formulations that do not require cold chain storage. The MATRIX formulation and drying platform supports thermostable vaccine, therapeutic, and diagnostic products. The company aims to enable long-term immune responses and easier distribution, including in low-resource settings. Its technology supports oncology and infectious disease applications, including therapies that promote durable anti-tumor immunity and improved treatment outcomes. Founded in 2011 and based in Boston, the company positions its platforms to enable stable, targeted delivery and potentially reduce treatment burden for patients.

Chlorion Pharma is a start-up biotechnology company focused on developing innovative therapeutics for the treatment of pain and epilepsy. The company's approach targets neuronal hyperactivity by correcting aberrant chloride homeostasis, aiming to provide effective solutions for patients suffering from neuropathic diseases. Through its research and development efforts, Chlorion Pharma seeks to address unmet medical needs in the field of neurology, offering the potential for improved therapeutic outcomes for individuals affected by these conditions.

Pegase Medical Inc., a Quebec City-based developer of natural base products for the animal market.